Clinical Trial Update: A Study of Olaratumab (IMC-3G3) in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for olaratumab (IMC-3G3) in prostate cancer has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-11-02